InspireMD, Inc. (NSPR)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 2 | 4 | 5 | 6 | 7 | 9 | 11 | 10 |
| Operating profit | $m | -49 | -54 | ||||||
| Net profit | $m | -11 | -15 | -18 | -20 | -32 | -49 | -39 | -53 |
| EPS reported | $ | -0.76 | -0.50 | ||||||
| Operating cashflow per share | $ | -0.48 | -0.56 | ||||||
| Capex per share | $ | 0.02 | 0.02 | ||||||
| FCF per share | $ | -0.50 | -0.58 | ||||||
| Free cash flow | $m | -37 | -42 | ||||||
| Net debt | $m | -54 | -30 | ||||||
| Book value equity | $m | 55 | 32 | ||||||
| Book value per share | $ | 0.75 | 0.43 | ||||||
| Number of shares | m | 73.47 | 73.47 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 2.37 | 4.15 | ||||||
| P/S LTM | x | 14.56 | 12.06 | ||||||
| P/FCF LTM | x | -3.56 | -3.08 | ||||||
| EV/EBITDA LTM | x | -2.59 | -3.30 | ||||||
| EV/Sales LTM | x | 13.93 | 3.03 | ||||||
| Earnings Yield LTM | % | -37.31% | -53.35% | ||||||
| FCF Yield | % | -28.11% | -32.47% | ||||||
| Quality | |||||||||
| ROE | % | -88.38% | -79.21% | ||||||
| ROIC | % | -82.18% | -1.53% | ||||||
| Operating margin | % | -5.47% | -4.94% | ||||||
| Gross margin | % | +29.50% | +18.05% | ||||||
| FCF/Sales | % | -409.46% | -391.67% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +28.11% | +54.67% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -11.17 | -21.56 | ||||||
| Net Debt/EBITDA | x | 0.12 | 0.35 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | +4.28% | ||||||
| Net debt/Equity | x | -0.98 | -0.97 | ||||||
| Gross debt/equity | x | 0.06 | 0.06 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to address various vascular and coronary diseases. The company's offerings, distributed through a network of local partners, reach markets across Europe, Latin America, the Middle East, and Asia Pacific. Key products include the CGuard carotid embolic prevention system, specifically designed for carotid artery procedures, and the MGuard Prime embolic protection systems. The MGuard Prime systems are crucial for patients experiencing acute coronary syndromes, notably acute myocardial infarction, and those undergoing saphenous vein graft coronary interventions or bypass surgery. InspireMD is also developing PVGuard, an innovative solution combining a MicroNet mesh sleeve with a self-expandable stent, aimed at peripheral vascular applications.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to address various vascular and coronary diseases. The company's offerings, distributed through a network of local partners, reach markets across Europe, Latin America, the Middle East, and Asia Pacific. Key products include the CGuard carotid embolic prevention system, specifically designed for carotid artery procedures, and the MGuard Prime embolic protection systems. The MGuard Prime systems are crucial for patients experiencing acute coronary syndromes, notably acute myocardial infarction, and those undergoing saphenous vein graft coronary interventions or bypass surgery. InspireMD is also developing PVGuard, an innovative solution combining a MicroNet mesh sleeve with a self-expandable stent, aimed at peripheral vascular applications.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free